Business, energy, technology, markets and global industry news from Business News Today

HARMONi-6

PharmaDeviceNews HARMONi-6
Summit Therapeutics enters a pivotal phase for ivonescimab as the oncology developer deploys its $690.7 million cash position toward an upcoming FDA decision, HARMONi-3 data and an expanding late-stage lung cancer programme. Representative image.
Pharma & Biotech

Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything

Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.

Read More
Representative image: A clinician reviews lung cancer imaging as ivonescimab survival data from the HARMONi-6 study raise fresh questions about the future of first-line squamous non-small cell lung cancer treatment.
Pharma & Biotech

Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?

Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.

Read More
Pharma & Biotech

Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?

Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.

Read More